Trial Evaluating Modified FOLFIRINOX and Modified FOLFOX in the Treatment of Locally Advanced or Metastatic Small Bowel Adenocarcinoma

Randomized, non-comparative, open-label, multi-centre Phase II study to evaluate modified FOLFIRINOX and modified FOLFOX in the locally advenced or metastatic small bowel adenocarcinoma. The primary objective is to assess the percentage of patients alive without prograssion at 8 months.

NCT Number	NCT06278545
Lead Sponsor	Centre Hospitalier Universitaire Dijon
Conditions	Locally Advanced or Metastatic Small Bowel Adenocarcinoma
Enrollment	130 participants
Start Date	2024-02-16
Primary Completion	2027-02 (estimated)
Study Completion	2029-02 (estimated)
Updated on ClinicalTrials.gov	2024-02-26